Chronic kidney disease (CKD) affects 1 in 7 American adults, increasing the risk of progression, cardiovascular events, and mortality. Despite its prevalence, only 9% of patients are aware of their condition. Screening is recommended for high-risk populations, including those with diabetes, hypertension, and age over 50. CKD is diagnosed using estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (uACR). It is staged using the C-G-A classification and managed with lifestyle changes, interdisciplinary care, and pharmacotherapy such as ACE inhibitors, ARBs, SGLT2 inhibitors, and MRAs. Screening is cost-effective and can prevent progression to dialysis and reduce cardiovascular events. High-risk groups include those with diabetes (40% prevalence), hypertension (22%), and those over 50 (34%). Screening should occur at diagnosis for diabetes and five years post-diagnosis for hypertension. CKD screening is also recommended for those over 50, as it is cost-effective. Screening methods include eGFR and uACR, with uACR being the preferred method for routine practice. Albuminuria is a significant risk factor for CKD progression and cardiovascular events. CKD management includes blood pressure and glycemic control, appropriate pharmacotherapy, and referral to a nephrologist. Statins are recommended for CKD patients to reduce cardiovascular risk. Early referral to a nephrologist improves outcomes. Screening and management of CKD are essential for reducing morbidity and mortality, promoting health equity, and ensuring cost-effectiveness.Chronic kidney disease (CKD) affects 1 in 7 American adults, increasing the risk of progression, cardiovascular events, and mortality. Despite its prevalence, only 9% of patients are aware of their condition. Screening is recommended for high-risk populations, including those with diabetes, hypertension, and age over 50. CKD is diagnosed using estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (uACR). It is staged using the C-G-A classification and managed with lifestyle changes, interdisciplinary care, and pharmacotherapy such as ACE inhibitors, ARBs, SGLT2 inhibitors, and MRAs. Screening is cost-effective and can prevent progression to dialysis and reduce cardiovascular events. High-risk groups include those with diabetes (40% prevalence), hypertension (22%), and those over 50 (34%). Screening should occur at diagnosis for diabetes and five years post-diagnosis for hypertension. CKD screening is also recommended for those over 50, as it is cost-effective. Screening methods include eGFR and uACR, with uACR being the preferred method for routine practice. Albuminuria is a significant risk factor for CKD progression and cardiovascular events. CKD management includes blood pressure and glycemic control, appropriate pharmacotherapy, and referral to a nephrologist. Statins are recommended for CKD patients to reduce cardiovascular risk. Early referral to a nephrologist improves outcomes. Screening and management of CKD are essential for reducing morbidity and mortality, promoting health equity, and ensuring cost-effectiveness.